Korea United Pharm Inc. (033270.KS)
KRW 19950.0
(-2.44%)
KRW 19950.0
(-2.44%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 118.21 Billion KRW | 21.78% |
| 2022 | 97.07 Billion KRW | 8.54% |
| 2021 | 89.43 Billion KRW | 5.14% |
| 2020 | 85.06 Billion KRW | -9.11% |
| 2019 | 93.58 Billion KRW | 6.68% |
| 2018 | 87.72 Billion KRW | 9.46% |
| 2017 | 80.14 Billion KRW | 14.97% |
| 2016 | 69.71 Billion KRW | 7.91% |
| 2015 | 64.6 Billion KRW | 5.73% |
| 2014 | 61.1 Billion KRW | 6.59% |
| 2013 | 57.32 Billion KRW | 3.17% |
| 2012 | 55.56 Billion KRW | -16.47% |
| 2011 | 66.52 Billion KRW | 3.45% |
| 2010 | 64.3 Billion KRW | 7.08% |
| 2009 | 60.05 Billion KRW | 10.09% |
| 2008 | 54.55 Billion KRW | 56.02% |
| 2007 | 34.96 Billion KRW | -11.11% |
| 2006 | 39.33 Billion KRW | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 56.3 Billion KRW | -56.05% |
| 2024 Q1 | 56.3 Billion KRW | 81.24% |
| 2024 Q2 | 58.46 Billion KRW | 3.83% |
| 2023 Q4 | 31.06 Billion KRW | 225.95% |
| 2023 Q3 | -24.66 Billion KRW | 2.06% |
| 2023 Q2 | -25.18 Billion KRW | -194.6% |
| 2023 Q1 | 26.62 Billion KRW | 11.93% |
| 2023 FY | 118.21 Billion KRW | 21.78% |
| 2022 FY | 97.07 Billion KRW | 8.54% |
| 2022 Q3 | 24.31 Billion KRW | -2.73% |
| 2022 Q1 | 23.97 Billion KRW | 0.69% |
| 2022 Q2 | 24.99 Billion KRW | 4.28% |
| 2022 Q4 | 23.78 Billion KRW | -2.19% |
| 2021 Q3 | 22.96 Billion KRW | 2.94% |
| 2021 Q4 | 23.8 Billion KRW | 3.68% |
| 2021 Q1 | 20.35 Billion KRW | -7.15% |
| 2021 FY | 89.43 Billion KRW | 5.14% |
| 2021 Q2 | 22.3 Billion KRW | 9.6% |
| 2020 Q1 | 22.88 Billion KRW | 0.36% |
| 2020 Q2 | 19.52 Billion KRW | -14.65% |
| 2020 Q3 | 20.73 Billion KRW | 6.18% |
| 2020 Q4 | 21.92 Billion KRW | 5.72% |
| 2020 FY | 85.06 Billion KRW | -9.11% |
| 2019 Q1 | 24.13 Billion KRW | -11.3% |
| 2019 Q3 | 22.72 Billion KRW | -5.0% |
| 2019 FY | 93.58 Billion KRW | 6.68% |
| 2019 Q4 | 22.79 Billion KRW | 0.32% |
| 2019 Q2 | 23.92 Billion KRW | -0.89% |
| 2018 FY | 87.72 Billion KRW | 9.46% |
| 2018 Q4 | 27.21 Billion KRW | 33.41% |
| 2018 Q1 | 20.06 Billion KRW | -3.82% |
| 2018 Q2 | 20.04 Billion KRW | -0.08% |
| 2018 Q3 | 20.39 Billion KRW | 1.74% |
| 2017 Q1 | 19.6 Billion KRW | 14.54% |
| 2017 Q3 | 18.84 Billion KRW | -9.58% |
| 2017 Q2 | 20.83 Billion KRW | 6.29% |
| 2017 FY | 80.14 Billion KRW | 14.97% |
| 2017 Q4 | 20.86 Billion KRW | 10.72% |
| 2016 Q2 | 17.44 Billion KRW | -0.08% |
| 2016 Q4 | 17.11 Billion KRW | -3.24% |
| 2016 Q3 | 17.68 Billion KRW | 1.38% |
| 2016 FY | 69.71 Billion KRW | 7.91% |
| 2016 Q1 | 17.46 Billion KRW | 0.0% |
| 2015 FY | 64.6 Billion KRW | 5.73% |
| 2015 Q4 | - KRW | -100.0% |
| 2015 Q3 | 16.47 Billion KRW | 6.68% |
| 2015 Q2 | 15.44 Billion KRW | -5.54% |
| 2015 Q1 | 16.34 Billion KRW | 3.5% |
| 2014 Q4 | 15.79 Billion KRW | 6.08% |
| 2014 FY | 61.1 Billion KRW | 6.59% |
| 2014 Q1 | 15.23 Billion KRW | 1.37% |
| 2014 Q3 | 14.89 Billion KRW | -1.93% |
| 2014 Q2 | 15.18 Billion KRW | -0.33% |
| 2013 Q4 | 15.02 Billion KRW | 7.12% |
| 2013 FY | 57.32 Billion KRW | 3.17% |
| 2013 Q1 | 13.32 Billion KRW | 3.12% |
| 2013 Q2 | 14.94 Billion KRW | 12.23% |
| 2013 Q3 | 14.02 Billion KRW | -6.16% |
| 2012 Q3 | 14.39 Billion KRW | 5.13% |
| 2012 Q4 | 12.91 Billion KRW | -10.25% |
| 2012 FY | 55.56 Billion KRW | -16.47% |
| 2012 Q1 | 13.09 Billion KRW | 0.0% |
| 2012 Q2 | 13.69 Billion KRW | 4.54% |
| 2011 Q3 | 14.06 Billion KRW | -3.93% |
| 2011 Q2 | 14.63 Billion KRW | -6.06% |
| 2011 FY | 66.52 Billion KRW | 3.45% |
| 2011 Q1 | 15.58 Billion KRW | -10.0% |
| 2011 Q4 | - KRW | -100.0% |
| 2010 Q2 | 16.36 Billion KRW | 7.34% |
| 2010 Q1 | 15.24 Billion KRW | 0.52% |
| 2010 Q4 | 17.31 Billion KRW | 12.49% |
| 2010 Q3 | 15.38 Billion KRW | -5.95% |
| 2010 FY | 64.3 Billion KRW | 7.08% |
| 2009 Q4 | 15.16 Billion KRW | -2.65% |
| 2009 FY | 60.05 Billion KRW | 10.09% |
| 2009 Q1 | 13.82 Billion KRW | -1.86% |
| 2009 Q2 | 15.48 Billion KRW | 11.95% |
| 2009 Q3 | 15.57 Billion KRW | 0.63% |
| 2008 Q4 | 14.09 Billion KRW | 2.97% |
| 2008 Q2 | 13.45 Billion KRW | -0.57% |
| 2008 Q1 | 13.52 Billion KRW | 0.0% |
| 2008 FY | 54.55 Billion KRW | 56.02% |
| 2008 Q3 | 13.68 Billion KRW | 1.75% |
| 2007 Q2 | 10.67 Billion KRW | 0.0% |
| 2007 Q3 | 11.45 Billion KRW | 7.31% |
| 2007 FY | 34.96 Billion KRW | -11.11% |
| 2006 FY | 39.33 Billion KRW | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Dongwha Pharm.Co.,Ltd | 165.11 Billion KRW | 28.404% |
| Yuhan Corporation | 489.94 Billion KRW | 75.872% |
| Yuhan Corporation | 489.94 Billion KRW | 75.872% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -150.168% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -150.168% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -150.168% |
| Ildong Holdings Co., Ltd. | 278.43 Billion KRW | 57.544% |
| Samil Pharmaceutical Co.,Ltd | 65.75 Billion KRW | -79.789% |
| Dong-A Socio Holdings Co., Ltd. | 297.99 Billion KRW | 60.33% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | 50.52% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | 50.52% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | 50.52% |
| SAMSUNG PHARM. Co., LTD. | 41.78 Billion KRW | -182.88% |
| Chong Kun Dang Holdings Corp. | 350.71 Billion KRW | 66.294% |
| Dong Sung Bio Pharm.Co.,Ltd. | 40.05 Billion KRW | -195.143% |
| HANDOK Inc. | 153.76 Billion KRW | 23.122% |
| Jeil Pharma Holdings Inc | 193.66 Billion KRW | 38.959% |
| Kukje Pharma Co., Ltd. | 69.21 Billion KRW | -70.796% |
| Bukwang Pharmaceutical Co., Ltd. | 87.54 Billion KRW | -35.037% |
| Aprogen pharmaceuticals,Inc. | 58.64 Billion KRW | -101.578% |
| Ilsung Pharmaceuticals Co., Ltd. | 42.47 Billion KRW | -178.335% |
| Daewon Pharmaceutical Co., Ltd. | 221.99 Billion KRW | 46.75% |
| Yungjin Pharm. Co., Ltd. | 69.46 Billion KRW | -70.169% |
| Boryung Corporation | 285.16 Billion KRW | 58.545% |
| Hyundai Pharmaceutical Co., Ltd. | 68.31 Billion KRW | -73.053% |
| Samjin Pharmaceuticals Co., Ltd. | 126.39 Billion KRW | 6.471% |
| Ilyang Pharmaceutical Co.,Ltd | 174.14 Billion KRW | 32.119% |
| Ilyang Pharmaceutical Co.,Ltd | 174.14 Billion KRW | 32.119% |
| Suheung Co., Ltd. | 56.03 Billion KRW | -110.976% |
| Kwang Dong Pharmaceutical Co., Ltd. | 249.12 Billion KRW | 52.548% |
| Hanall Biopharma Co.,Ltd | 71.98 Billion KRW | -64.224% |
| Whan In Pharm Co.,Ltd. | 66.41 Billion KRW | -77.986% |
| MYUNGMOON Pharm co.,Ltd | 93.55 Billion KRW | -26.362% |
| Shin Poong Pharm.Co.,Ltd. | 127.66 Billion KRW | 7.406% |
| Shin Poong Pharm.Co.,Ltd. | 127.66 Billion KRW | 7.406% |
| CKD Bio Corp. | 25.19 Billion KRW | -369.182% |
| Daewoong pharmaceutical Co.,Ltd | 560.43 Billion KRW | 78.907% |
| JW Holdings Corporation | 301.25 Billion KRW | 60.76% |
| REYON Pharmaceutical Co., Ltd. | 75.04 Billion KRW | -57.515% |
| Hanmi Pharm. Co., Ltd. | 610.97 Billion KRW | 80.651% |
| Dong-A ST Co., Ltd. | 306.95 Billion KRW | 61.489% |
| Chong Kun Dang Pharmaceutical Corp. | 408.65 Billion KRW | 71.073% |
| JW Lifescience Corporation | 20.26 Billion KRW | -483.439% |
| Ildong Pharmaceutical Co., Ltd. | 260.95 Billion KRW | 54.7% |
| Jeil Pharmaceutical Co.,Ltd | 174.92 Billion KRW | 32.421% |
| Hana Pharm Co., Ltd. | 114.72 Billion KRW | -3.041% |